BCMA Targeted Therapies Pipeline Summary

DelveInsight’s, “BCMA Targeted Therapies - Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 77+ pipeline drugs in BCMA Targeted Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

BCMA Targeted Therapies: Understanding

BCMA Targeted Therapies: Overview

B-cell maturation antigen (BCMA) has emerged as one of the most actively pursued targets in modern oncology drug development, owing to its restricted expression on plasma cells and its central role in plasma cell survival and proliferation B-cell maturation antigen (BCMA) is a plasma cell surface protein central to the proliferation and survival of malignant plasma cells. This selective expression profile has made BCMA an attractive target for antibody- and cell-based therapeutics, leading to the development of multiple modalities designed to direct immune-mediated killing toward BCMA-expressing cells the major classes explored include chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies that co-engage BCMA and CD3 on T cells, in addition to antibody-drug conjugates.

BCMA-targeted therapies fall into three main classes that are CAR T-cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs) the three main categories of targeted therapies for BCMA include bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor modified T-cell therapy. CAR-T therapies genetically engineer a patient's own T cells to target BCMA-expressing cells, while BsAbs redirect T cells by simultaneously engaging BCMA and CD3, offering an off-the-shelf option without CAR-T's manufacturing bispecific antibodies provide an off-the-shelf treatment option, especially useful for patients who may not be candidates for CAR-T therapy due to manufacturing time or prior lympho depletion requirements. ADCs instead deliver a cytotoxic payload directly to tumor cells via a BCMA-directed antibody.

B-cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a cell-surface protein expressed predominantly on mature B cells and plasma cells and plays an important role in their proliferation, differentiation, and survival. Its restricted expression pattern and presence on plasma cells make BCMA an attractive target for therapeutic development. BCMA-targeted therapies are designed to recognize and eliminate BCMA-expressing cells through different immune-mediated mechanisms. Major therapeutic approaches include chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell–engaging antibodies, and antibody–drug conjugates (ADCs). CAR-T therapies genetically modify T cells to express a BCMA-directed CAR, enabling them to recognize BCMA-positive cells and induce their destruction, whereas bispecific antibodies simultaneously bind BCMA on the target cell and CD3 on T cells to bring the two cells into close proximity and activate T-cell–mediated cytotoxicity. ADCs use a BCMA-binding antibody to selectively deliver a cytotoxic payload to BCMA-expressing cells. The therapeutic potential of BCMA targeting has driven continued development of these approaches, although challenges such as antigen escape, soluble BCMA, treatment resistance, cytokine release syndrome, and neurotoxicity remain important considerations for improving the safety and durability of BCMA-directed therapies.

BCMA-targeted therapies CAR-T, bispecific antibodies, and ADCs have transformed relapsed/refractory multiple myeloma treatment, delivering deep, durable responses even in heavily pretreated patients B-cell maturation antigen-targeted therapies including CAR T-cell therapies and bispecific antibodies have revolutionized the treatment landscape for relapsed/refractory multiple myeloma, offering deep and durable responses even in heavily pretreated patients. The BCMA therapeutic landscape is advancing through next-generation and dual-targeting therapies, including CAR-T cells and trispecific antibodies, with increasing evaluation in earlier lines of treatment and newly diagnosed disease.

"BCMA Targeted Therapies- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the BCMA Targeted Therapies pipeline landscape is provided which includes the disease overview and BCMA Targeted Therapies treatment guidelines. The assessment part of the report embraces, in depth BCMA Targeted Therapies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, BCMA Targeted Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence BCMA Targeted Therapies R&D. The therapies under development are focused on novel approaches to treat/improve BCMA Targeted Therapies.

BCMA Targeted Therapies Emerging Drugs Chapters

This segment of the BCMA Targeted Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

BCMA Targeted Therapies Emerging Drugs

• AZD0120: Astrazeneca

AZD0120 is an investigational autologous dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy, formerly known as GC012F, designed to simultaneously target B-cell maturation antigen (BCMA) and CD19. BCMA is highly expressed on plasma cells, including malignant plasma cells, while CD19 is expressed on B cells and certain plasma-cell populations. AZD0120 genetically engineers a patient’s T cells to express a CAR that recognizes both BCMA- and CD19-expressing cells, thereby activating T-cell signaling and inducing targeted cytotoxicity and elimination of these cells. By simultaneously targeting the two antigens, AZD0120 is intended to provide broader depletion of disease-associated B-cell and plasma-cell populations compared with single-antigen targeting. Currently, the drug is in Phase III of its development for the treatment of relapsed or refractory multiple myeloma.

• Descartes-08: Cartesian Therapeutics

Descartes-08 is an autologous, BCMA-targeted messenger RNA (mRNA) chimeric antigen receptor T-cell (CAR-T) therapy designed for autoimmune diseases. It uses a patient’s own T cells, which are transiently engineered with mRNA encoding an anti-BCMA CAR, enabling the T cells to recognize and eliminate BCMA-expressing pathogenic plasma cells, plasmablasts, and plasmacytoid dendritic cells. By selectively depleting these BCMA-positive cell populations, Descartes-08 is intended to reduce the production of disease-causing autoantibodies and inflammatory signaling, thereby producing a targeted immune reset while preserving broader protective B-cell and immune function. Unlike conventional integrating CAR-T approaches, its mRNA-based CAR expression is transient, allowing temporary targeting of pathogenic cells without genomic integration.

• CB-011: Caribou Biosciences

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM). To the company’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein to blunt immune-mediated rejection. The FDA granted CB-011 RMAT, Fast Track, and Orphan Drug designations for relapsed or refractory multiple myeloma (r/r MM). Currently, the drug is in Phase I of its development for the treatment of relapsed or refractory multiple myeloma.

• SYS6020: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SYS6020 is an autologous B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy manufactured using an mRNA–lipid nanoparticle (LNP)-based transfection approach. The therapy transiently equips a patient’s own T cells with a CAR capable of specifically recognizing BCMA, which is expressed on plasma cells and pathogenic BCMA-positive B-cell populations. Upon recognition of BCMA-expressing cells, SYS6020 activates the engineered T cells and induces targeted cytotoxicity, resulting in the elimination of these cells. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Refractory Active Systemic Lupus Erythematosus.

• SG227: Sana Biotechnology

SG227 is a CD8-targeted fusosome designed to deliver genetic material directly to CD8+ T cells, enabling them to become BCMA-directed CAR T cells. The fusosome targets CD8+ T cells and delivers the genetic payload encoding a BCMA-directed chimeric antigen receptor (CAR); the resulting CAR T cells are intended to recognize and target BCMA-expressing myeloma cells, thereby enabling an in vivo CAR T-cell approach for multiple myeloma. Currently, the drug is being evaluated in the Preclinical stage of its development.

Further product details are provided in the report……..

BCMA Targeted Therapies: Therapeutic Assessment

This segment of the report provides insights about the different BCMA Targeted Therapies drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in BCMA Targeted Therapies

There are approx. 75+ key companies which are developing the BCMA Targeted Therapies. The companies which have their BCMA Targeted Therapies drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca, and others.

• Phases

DelveInsight’s report covers around 77+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

BCMA Targeted Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

BCMA Targeted Therapies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BCMA Targeted Therapies therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BCMA Targeted Therapies drugs.

BCMA Targeted Therapies Report Insights

• BCMA Targeted Therapies Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

BCMA Targeted Therapies Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing BCMA Targeted Therapies drugs?
• How many BCMA Targeted Therapies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BCMA Targeted Therapies?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the BCMA Targeted Therapies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BCMA Targeted Therapies and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Cartesian Therapeutics
• Caribou Biosciences
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sana Biotechnology
• iCell Gene Therapeutics
• Qilu Pharmaceutical
• UCB Biopharma
• Gilead Sciences
• AbelZeta Pharma
• Nexcella Inc.
• Johnson & Johnson
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Umoja Biopharma

Key Products

• AZD0120
• Descartes-08
• CB-011
• SYS6020
• SG227
• CM336
• QLS4131
• Cizutamig
• Anito-cel
• C-CAR168
• NXC-201
• ISB 2001
• Ramantamig
• HDP-101
• UB-VV500